Lee Financial’s Agios Pharmaceuticals AGIO Stock Holding History

Lee Financial’s Portfolio AGIO Stock Details AGIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-30	Closed	-$1K	–	753
2021 Q4	$1K	Buy	+30	New	+$1.21K	﹤0.01%	808

Other funds holding AGIO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Lee Financial's AGIO Position: Q1 2022 in Review

Lee Financial sold out of Agios Pharmaceuticals (AGIO) in Q1 2022, closing a stake of 30 shares — an estimated $1K sold.

Lee Financial first reported a position in AGIO in Q4 2021 and held it in 1 quarter. The position peaked at $1K in Q4 2021. 160 funds tracked by Wall St. Rank hold AGIO as of Q1 2022.

Lee Financial reported no remaining Agios Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
Lee Financial sold 30 Agios Pharmaceuticals shares in Q1 2022, an estimated $1K.
Lee Financial first reported a position in Agios Pharmaceuticals in Q4 2021 and held it in 1 quarter.
Lee Financial's Agios Pharmaceuticals position peaked at $1K in Q4 2021.
160 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q1 2022.

Based on Lee Financial's 13F filing for Q1 2022, filed 11 May 2022.